Diagnostic Imaging for Clear Cell Renal Cell Carcinoma

• Status: Terminated
• Trial end date: 2018-09-12
• Target enrollment: 0
• Participant gender: All

Summary

The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Skane
• Collaborator: Lund University

Criteria

Inclusion Criteria:

• suspected kidney cancer diagnosis

• suspected spread of the cancer

• patient is scheduled for surgery alternatively biopsy of kidney tumor

• patient is 18 years or older

• the patient has given their consent to participate in the study

• female patients of reproductive age displays negative pregnancy test

Exclusion Criteria:

• known or suspected allergy to Ioflupane or sodium acetate or acetic acid or ethanol

• patient suffers from moderate to severe renal impairment and exhibits glomerular filtration rate (GFR) <40

• patient is medicated for Parkinson's disease

• patient is medicated with any of the following medications: amphetamine, benzatropine, buproprion, cocaine, mazindol, methylphenidate, phentermine, sertraline, levodopa, dexamphetamine, lisdexamphetamine, modafinil, moclobemid, venlafaxine

• patient is pregnant

• breastfeeding

• patient suffers from mental inability unwillingness or language difficulties resulting in difficulty in understanding the meaning of taking part in the study